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Background: The homeobox containing transcription factor Uncx4.1 is, amongst others, expressed in the mouse
midbrain. The early expression of this transcription factor in the mouse, as well as in the chick midbrain, points to a
conserved function of Uncx4.1, but so far a functional analysis in this brain territory is missing. The goal of the
current study was to analyze in which midbrain neuronal subgroups Uncx4.1 is expressed and to examine whether
this factor plays a role in the early development of these neuronal subgroups.
Results: We have shown that Uncx4.1 is expressed in GABAergic, glutamatergic and dopaminergic neurons in the
mouse midbrain. In midbrain dopaminergic (mDA) neurons Uncx4.1 expression is particularly high around E11.5
and strongly diminished already at E17.5. The analysis of knockout mice revealed that the loss of Uncx4.1 is
accompanied with a 25% decrease in the population of mDA neurons, as marked by tyrosine hydroxylase (TH),
dopamine transporter (DAT), Pitx3 and Ngn2. In contrast, the number of glutamatergic Pax6-positive cells was
augmented, while the GABAergic neuron population appears not affected in Uncx4.1-deficient embryos.
Conclusion: We conclude that Uncx4.1 is implicated in the development of mDA neurons where it displays a
unique temporal expression profile in the early postmitotic stage. Our data indicate that the mechanism underlying
the role of Uncx4.1 in mDA development is likely related to differentiation processes in postmitotic stages, and
where Ngn2 is engaged. Moreover, Uncx4.1 might play an important role during glutamatergic neuronal
differentiation in the mouse midbrain.
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Midbrain dopaminergic (mDA) neurons are organized in
three different areas in the mammalian midbrain: the
substantia nigra pars compacta (SNpc), the ventral teg-
mental area (VTA), and the retrorubal field (RRF). mDA
neurons from the SNpc are associated with the nigros-
triatal pathway while neurons from the VTA and RRF
act in the mesolimbic pathway. The degeneration of
neurons of the nigrostriatal pathway in Parkinson’s dis-
ease has attracted many researchers to identify and study* Correspondence: amansou@gwdg.de
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reproduction in any medium, provided the orthe transcriptional network controlling mDA neuron
development. Although several factors and determinants
were found to be crucial for mDA neuron development
like Ngn2 [1,2], Lmx1a/1b [3], Foxa1/2 [4,5], Nurr1 [6],
Otx2 [7] and ß-Catenin [8,9] the molecular mechanisms
controlling specification and differentiation of these neu-
rons are not fully understood, and the knowledge of the
transcriptional network is still incomplete.
Uncx4.1 is a homeobox containing transcription factor
with 88% identity to Unc4 from C.elegans [10,11]. In mice,
it is expressed in the caudal half of the somite, the devel-
oping kidney, and the central nervous system [10,11].
Functional analysis using knockout mice indicated that
Uncx4.1 is required for the proper development of the
axial skeleton [12,13]. In the central nervous systemtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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alon and the telencephalon [10,11]. Recent findings pro-
vided evidence for the involvement of Uncx4.1 in late
development of the pituitary neural lobe [14], and the
proliferation of neural progenitors, as well as neuronal
survival in the mouse olfactory epithelium [15]. In con-
trast, the possible role of Uncx4.1 in the developing
midbrain has not been addressed.
Here we show that in the ventral midbrain Uncx4.1 is
found to localize with dopaminergic, glutamatergic and
GABAergic postmitotic neurons at embryonic day (E) 11.5
of gestation. Molecular analysis of global loss-of-function
mouse mutant revealed that mDA neurons are reduced in
the absence of Uncx4.1, and this is corroborated by a par-
tial downregulation of Ngn2. Interestingly the number of
glutamatergic Pax6-expressing cells in the midbrain is
increased at E13.5 while the Nkx6.1-positive neurons are
not affected.Figure 1 The expression of Uncx4.1 in the developing mouse midbra
(B-E) Immunohistochemistry (IHC) on coronal (D, C, E) and sagittal (B) secti
developing midbrain at E11.5 (B-C), E13.5 (D) and E17.5 (E). (B, C) At E11.5 U
midbrain. (D, E) At E13.5 and E17.5 Uncx4.1 expression appears in a salt-and
expression can be detected in the basal plate. (F-H) Double IHC with anti-U
E11.5. (G, H) Showing higher magnifications of F, referring to the labeling
Tju1-negative cell. E, embryonic day.Results
Uncx4.1 is expressed in the mantle layer of the
developing midbrain
In the central nervous system Uncx4.1 transcripts first
appeared at E9.5 in the mesencephalon [10,13], but a
detailed expression analysis of Uncx4.1 in the developing
mouse midbrain at subsequent stages so far has not been
performed. At E10.5, transcripts were detected in the
mantle layer of the basal and alar plate (data not shown).
At E11.5 the signal in the basal and alar plate was
increased and Uncx4.1 protein was detected in the
ventral-most midbrain, close to the mesencephalic flexure
(Figure 1B-C, Figure 2A and data not shown). At E13.5
Uncx4.1 expression was scattered and the strongest label-
ing was observed in the lateral part of the basal plate
(Figure 1D). At E17.5, Uncx4.1 expression remained scat-
tered and the transcripts were distributed over the whole
midbrain (Figure 1E). At all analyzed stages the expressionin. (A) X-gal staining of Uncx4.1+/− embryo at E11.5.
ons of wild-type embryos showing the expression of Uncx4.1 in the
ncx4.1 is expressed in the whole mantle layer of the embryonic
-pepper pattern with Uncx4.1-negative cells. The strongest Uncx4.1
ncx4.1 and anti-Tuj1 on coronal sections of a wild-type embryo at
in the white box. The white arrow marks an Uncx4.1-positve,
Figure 2 Uncx4.1 expression in embryonic mouse midbrain compared with expression of neuronal subtype markers. (A-L) In situ
hybridization analysis of Uncx4.1 (A, C, E, G, I, K), Nkx2.2 (B), Helt (D), Gad67 (F), Lmx1a (H), Ngn2 (J) and Nkx6.1 (L) expression on coronal sections of
E11.5 or E12.5 wild-type mouse midbrain. (M, N) Immunohistochemistry (IHC) on E11.5 wild-type sections reveals that Uncx4.1 is co-expressed
with Foxa2 (M) and tyrosine hydroxylase (TH) (N) in postmitotic neurons of the ventral midbrain. (N’) Higher magnification of the inlay in N.
(O) IHC on E17.5 wild-type sections shows that at E17.5 most of the TH-positive cells have lost Uncx4.1 expression. (O’) Higher magnification of
the inlay in O. (O”) Higher magnification of the inlay in O’ showing that Uncx4.1 is not expressed in TH-positive cells at E17.5. E, embryonic day.
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of the midbrain and it was excluded from the midbrain
ventricular zone (VZ) , suggesting that it is confined to
postmitotic cells.
Double immunohistochemistry (IHC) with Uncx4.1 and
Tju1, a postmitotic neuron marker, revealed that nearly all
Uncx4.1-positive cells in the mantle layer also express
Tuj1 (Figure 1F-H). Only in the dorsal midbrain a few
Uncx4.1-positive and Tju1-negative cells could be detected
(Figure 1H). To examine which neuronal subtypes are
marked by Uncx4.1 we compared the expression pattern
of Uncx4.1 and the neuronal subtype markers: Lmx1a
(mDA neurons), Gad67, Nkx2.2, Helt (GABAergic neu-
rons), Nkx6.1 (glutamatergic neurons) and Ngn2 (mDA
and glutamatergic neurons). Shown in consecutive sec-
tions Uncx4.1 expression domain appeared to co-localizeat least partially with markers for most neuronal sub-
groups (Figure 2). This is true for Gad67, a general mar-
ker for GABAergic neurons in the mantle layer of the
whole midbrain (Figure 2E-F), as well as for Nkx2.2
(Figure 2A-B). As expected, Helt, which is expressed in
the ventricular zone of GABAergic neurons [16,17],
did not show overlapping expression with Uncx4.1
(Figure 2C-D), confirming that Uncx4.1 is absent from
mesencephalic GABAergic progenitors. Nkx6.1 labels a
specific subset of glutamatergic neurons in the ventricu-
lar zone and the mantle layer [17,18]. The partially over-
lapping expression domains of Nkx6.1 and Uncx4.1 in
the mantle layer indicate that Uncx4.1 is expressed in
midbrain glutamatergic neurons. In the most central
area of the medial ventral midbrain region, where ma-
ture mDA neurons arise, Uncx4.1 expression shared
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namely Lmx1a [3] and Ngn2 [1,2] (Figure 2G-H, I-J). In
order to examine whether Uncx4.1 is expressed in
GABAergic, glutamatergic and DA neurons we per-
formed IHC of Uncx4.1 together with tyrosine hydroxy-
lase (TH) or Foxa2. The dopaminergic neuron marker
TH started to be expressed around E11.5 in mature mDA
neurons. At this stage, most TH-positive neurons
expressed Uncx4.1 (Figure 2N), while this was not the case
at E17.5 (Figure 2O, O’), where Uncx4.1 is downregulated
in the VTA as well as SN. This finding suggests that
Uncx4.1 labels the majority of mature mDA neurons at
early development, but is rapidly downregulated when
matured. Co-localization of Foxa2 and Uncx4.1 was
observed in the whole mantle layer within the expression
domain of Foxa2, implying that Uncx4.1 is expressed in
mDA, GABAergic and glutamatergic neurons. Taken to-
gether, our data indicate that Uncx4.1 expression is not
confined to one neuronal lineage of mesencephalic neu-
rons. Rather, Uncx4.1 is expressed in most subtypes of
midbrain neurons, but is excluded from their proliferating
progenitors. These data suggest that Uncx4.1 is engaged in
processes of postmitotic differentiation.
Loss of Uncx4.1 causes reduction of mDA neurons in the
ventral midbrain
To examine the role of Uncx4.1 in mDA development, we
analyzed the expression of the dopamine transporter
(DAT) and TH in Uncx4.1-deficient embryos at E11.5 and
E17.5. We observed a clear reduction of DAT expression
at E17.5 (Figure 3E-F). Therefore, the number of mDA
neurons was assessed. Although the distribution of TH-
positive cells was normal in control and Uncx4.1 mutant
embryos, the number of TH-positive cells was found sig-
nificantly reduced (Figure 3A-D, Q). Interestingly, the de-
crease of TH-positive cells at E11.5 was similar to the
reduction observed at E17.5 (both −26%, Figure 3Q). The
partial loss of mDA neurons was further confirmed by
IHC for Pitx3, Nurr1, Calretinin and Calbindin. Pitx3 spe-
cifically labels mDA neurons [19-22] and the reduction of
Pitx3-positive cells (−31%), correlated with the diminution
of TH-positive cells (Figure 3I-J, R). A similar observation
was made for the Nurr1-labeled cells at E16.5 (reduction
of 24%). The number of Calbindin- and Calretinin-marked
cells, which are both expressed in a subset of mDA neu-
rons [23,24], was drastically decreased in Uncx4.1−/−
embryos (−43% and −58%, respectively, Figure 3M-P, R).
The early onset in the reduction of TH-positive cells in
the ventral midbrain and the corresponding downregula-
tion of all tested markers indicates that Uncx4.1 plays an
early role during development of mDA neurons. Further-
more, the dramatic reduction of Calbindin in the ventral
midbrain suggests that the mDA neurons of the VTA are
more affected as compared to the SN, since Calbindin ispreferentially expressed by VTA neurons [24]. To confirm
the findings that the mDA neurons of the VTA are
strongly affected in the absence of Uncx4.1, we analyzed
the expression of Otx2 at E17.5 in Uncx4.1-deficient
embryos. Otx2 is a transcription factor, which select-
ively labels postmitotic neurons of the VTA but not of
the SN at E17.5, and it is expressed in a subset of
Calbindin-positive neurons in this brain area [25].
Accordingly, Otx2 was downregulated in the VTA, con-
firming the findings from the Calbindin and Calretinin
staining (Figure 3O-P). The partial depletion of mDA
neurons may be a consequence of impaired cell prolif-
eration or survival defects. To examine both possibil-
ities we used 5-bromo-2'-deoxyuridine (BrdU) labeling
for proliferation analysis and the terminal deoxynucleo-
tidyl transferase dUTP nick end labeling (TUNEL) assay
for investigating apoptosis. At E11.5, 24 hours after BrdU
injection, as well as at E14.5, 45 minutes following BrdU
injection, no alterations in numbers of BrdU-positive cells
were observed (Additional file 1: Figure S1 A-B and data
not shown). To further confirm that the decreased number
of mDA neurons is not caused by alterations in cell prolif-
eration of this neuronal subgroup, we analyzed the BrdU-
labeled cells together with TH at E11.5, 24 hours following
BrdU-injection. In the wild-type (WT) as well as in mutant
embryos, we could not detect any difference in cell prolif-
eration (Additional file 1: Figure S1 C-D). Apoptotic cells
were also not detected at E11.5, and E17.5 (data not
shown). We concluded that defects in cell proliferation or
apoptosis are not involved in the DA neuron loss provoked
by Uncx4.1 depletion.
The expression of Ngn2 is downregulated in
Uncx4.1-deficient embryos
Since it appeared that mDA neuron reduction was not
caused by impaired proliferation or cell death, we next
investigated which factors may be affected by the ab-
sence of Uncx4.1, provoking the partial depletion of
mDA neurons. Since Lmx1a, Lmx1b, and Ngn2 are
involved for proper establishment of mDA neurons [1-
3,26,27], we analyzed their expression in E11.0 (Lmx1a),
E11.5 (Ngn2) or E12.5 (Lmx1a and Lmx1b) Uncx4.1−/−
embryos. As expected, Lmx1a and Lmx1b expression
was normal in Uncx4.1-deficient embryos (Figure 4A-B,
M-N and data not shown) but surprisingly the level of
Ngn2 mRNA was reduced (Figure 4, C-F). Interestingly,
the downregulation of Ngn2 transcripts was also
observed in the dorsal part of the midbrain (Figure 4, E-
F). Nurr1 expression was found nearly lacking in Ngn2
mutant mice at E11.5, but Nurr1-positve cells were res-
cued at later stages of development [1]. We therefore
investigated the expression of Nurr1 in the developing
Uncx4.1 mutants and observed at E11.5 a 28% loss of
Nurr1-positive cells compared to control embryos
Figure 3 Midbrain dopaminergic neurons are reduced in Uncx4.1−/− embryos. (A-D) Compared with control, tyrosine hydroxylase
(TH)-positive neurons are reduced in Uncx4.1−/− embryos at E11.5 (A-B) and E17.5 (C-D). (E-N) Immunohistochemistry (IHC) reveals a reduced
expression of dopamine transporter (DAT) (E-F), Pitx3 (G-H), Nurr1 (I-J) Calbindin (K-L) and Calretinin (M-N) in Uncx4.1−/− embryos compared to
control. (O-P) In situ hybridization (ISH) using a probe against Otx2 shows that the expression of Otx2 is reduced in Uncx4.1-deficient mice
compared to control. (Q, R) Quantification of TH-, Pitx3-, Calbindin- and Calretinin-positive cell numbers in the ventral midbrain of Uncx4.1-
deficient and control embryos. Error bars represent the standard deviation. P values <0.05 were assessed as statistically significant. E, embryonic
day; SN, substantia nigra; vMB: ventral midbrain, VTA, ventral tegmental area.
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E16.5 embryos (Figure 4, K-L, O). It has been previously
speculated that the rescue of Nurr1-positive cells in
Ngn2−/− embryos is due to a compensation by the pro-
neuronal gene Mash1 [1]. Its expression was completely
missing at the ventral midline in E11.5 Ngn2−/− embryos
and was recovered at E13.5 [1]. In Uncx4.1-deficient
midbrain the expression of Mash1 was found to benormal at E11.5 (Figure 4, G-H), indicating that unlike
in Ngn2−/− embryos, Nurr1-positive cells do not recover
in the absence of Uncx4.1. Since neurogenin 2 (Ngn2) is
required for the proper generation of mDA neurons,
these results indicate that the alteration of Ngn2 expres-
sion may be responsible for mDA neuron reduction in
the absence of Uncx4.1. We therefore analyzed the ex-
pression of Uncx4.1 and Ngn2 in more detail. Ngn2
Figure 4 Analysis of early mDA markers in Uncx4.1-deficient embryos showed that Ngn2-expression is reduced in mutant embryos.
A detailed analysis of Nurr1 expression in early and late embryonic stages of Uncx4.1−/− embryos revealed that the loss of Nurr1 is consistent
during midbrain dopaminergic neurons (mDA) development. (A-B) In situ hybridization (ISH) using Lmx1a reveals no difference in the expression
of Lmx1a in Uncx4.1−/− embryos at E11.0. (C-F) Reduction of Ngn2 in the ventral (C-D) and dorsal (E-F) midbrain of Uncx4.1−/− embryos compared
to control using ISH. (G-H) At E11.5 Mash1 expression is normal in Uncx4.1-deficient embryos compared to control. (I-L) Showing Nurr1
expression in control and Uncx4.1−/− embryos by immunohistochemistry (IHC). (O) Nurr1 is significantly reduced at E11.5 and E16.5 compared to
wild-type (WT) animals. Error bars represent the standard deviation. P values <0.05 were assessed as statistically significant. At least three animals
per stage and genotype were analyzed. (M, N) ISH using Lmx1b reveals no difference in Lmx1b expression in Uncx4.1−/− embryos. E, embryonic
day; vMB, ventral midbrain.
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ture mDA neurons around E10.75 [1]. At E11.5 Ngn2
and Uncx4.1 co-positive cells were detected in the
mantle layer of the ventral midbrain (Figure 5A-B, B’). It
appears that on the mRNA level more double-positive
cells were detected. The expression of Unxc4.1 in the
ventral midbrain of Ngn2−/− embryos was absent in the
most ventral part of the midbrain at E11.5 and E13.5
(Figure 5C-F), where mDA neurons are located. This is
consistent with the finding that Ngn2 is needed for the
generation of postmitotic mDA precursors and that the
progenitors are arrested in the absence of Ngn2 at E11.5
[1]. In contrast, Uncx4.1 expression in dorsal midbrain
was not affected (data not shown). To further analyzewhether Uncx4.1 and Ngn2 interact with each other, we
performed a co-immunoprecipitation assay. Our results
show that there is no interaction between Ngn2 and
Uncx4.1 (Additional file 2: Figure S2), suggesting that
these proteins do not undergo such a protein-protein
interaction. Uncx4.1 may still interact with Ngn2 pro-
moter. However, the palindromic putative binding site for
Uncx4.1 (TAATYNRATTA) could not be identified on the
Ngn2 locus. Taken together our findings suggest that the
partial depletion of mDA neurons in Uncx4.1-deficient
embryos may be a consequence of Ngn2 downregulation
during an early phase of mDA neuron differentiation.
How Uncx4.1 regulates Ngn2 expression remains elusive.
It is possible that the observed downregulation of Ngn2
Figure 5 Uncx4.1 and Ngn2 are co-expressed in some immature neurons in WT embryos, whereas Uncx4.1 is missing in the ventral
midline of Ngn2−/− embryos. (A-B) Analyzes of the expression of Uncx4.1 and Ngn2 using in situ hybridization ISH (A) and
immunohistochemistry (IHC) (B) revealed that Uncx4.1 and neurogenin 2 (Ngn2) are co-expressed in some immature neurons of the ventral
midbrain. It appears that on the mRNA level more double-positive cells are detected, as compared to IHC staining. (B’) display confocal
microscopy higher magnification of the inlay in B. (C-F) IHC against Uncx4.1 and green fluorescent protein (GFP) on coronal sections of E11.5
(C-D) and E13.5 (E-F) embryos, showing that Uncx4.1 is depleted at the midline in the ventral midbrain of Ngn2−/− embryos as compared to
WT. E, embryonic day; WT, wild-type.
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acts with Uncx4.1.
Normal development of midbrain GABAergic neurons in
the absence of Uncx4.1
Our analysis indicated that the loss of Uncx4.1 is accom-
panied by downregulation of Ngn2 expression, resulting
in a partial depletion of mDA, without affecting cell pro-
liferation or cell death. We therefore asked the question
whether a cell identity switch might have occurred in
the Uncx4.1-deficient midbrain and if these cells now
ectopically express GABAergic neuron markers. Kala et
al. showed that GABAergic neurons are located in the
VTA-SNpr in late development [28]. To investigate
whether mDA neurons switch their neuronal identityinto a GABAergic destiny in the absence of Uncx4.1, or
whether ectopic expression of GABAergic markers
occurs in the mDA domain, we studied the expression
of Helt and Mash1 which are essential for development
of midbrain GABAergic neurons [17,29,30]. The expres-
sion of Helt (Figure 6, A-B) and Mash1 (Figure 4, G-H)
was unaltered in the absence of Uncx4.1. To exclude the
possibility that Uncx4.1 influences GABAergic neuron de-
velopment postmitotically, we analyzed expression of
Gad67 and Olig2 in Uncx4.1-deficient embryos. While
Olig2 is confined to a specific subgroup of GABAergic
neurons in the mantle layer Gad67 is found in all these
neurons [17,28]. We did not observe a difference in the
expression of Gad67 or Olig2 at early and late develop-
mental stages (Figure 6, C-J). Together, these data
Figure 6 Midbrain GABAergic neurons are not affected in Uncx4.1-deficient embryos. (A-B) In situ hybridization (ISH) of Helt on E11.5
coronal sections reveals no difference in the absence of Uncx4.1. (C-F) The GABAergic marker GAD67 is expressed normally in Uncx4.1−/− embryos
at E11.5 (C-D) and E17.5 (E-F) compared to control animals. (G-J) Immunohistochemistry (IHC) against Olig2 shows no difference in control and
Uncx4.1−/− embryos at E11.5 (G-H) and E16.5 (I-J). E, embryonic day.
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in the ectopic activation of GABAergic neuron mar-
kers in the mDA domain. Therefore, we next examined
glutamatergic neuron development in Uncx4.1-deficient
embryos.Increased numbers of Pax6-positive glutamatergic
neurons in the ventral midbrain upon Uncx4.1 deficiency
Glutamatergic neurons are located in the embryonic
dorsal midbrain as well as in the ventral midbrain, and
adjacent to the mDA neuron domain [17,28,31]. Brn3a
Rabe et al. Neural Development 2012, 7:39 Page 9 of 16
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rons [32] that are located adjacent to the mDA neuron
domain [17,28,33]. Using in situ hybridization (ISH) we
observed an upregulation in the expression of Brn3a in
the ventral but not in the dorsal midbrain at all stagesFigure 7 (See legend on next page.)analyzed from E11.5 to E13.5 (Figure 7, A-B, and data
not shown). Recently, it was reported that Nkx6.1 plays
a crucial role for proper development of Brn3a-positive
red nucleus neurons [18]. Applying IHC no apparent dif-
ference in Nkx6.1 expression at E12.5 (Figure 7 C-D) or
(See figure on previous page.)
Figure 7 Analysis of midbrain glutamatergic markers. (A-B) Brn3a expression is increased in the ventral midbrain of Uncx4.1−/− embryos
compared to controls. (C-D) Nkx6.1 expression is normal in E12.5 embryos, indicating a proper establishment of glutamatergic progenitors.
(E-F) and (K-L) The numbers of Pax6-expressing cells are normal at E11.5 and E12.5 in Uncx4.1-deficient embryos compared to control.
(G-J) and (M-N) Immunohistochemistry (IHC) reveals increased numbers of Pax6-expressing cells at E13.5 and E17.5 in the absence of Uncx4.1.
(U) Quantification of Pax6-expressing cells in the ventral midbrain of Uncx4.1−/− and control embryos. Error bars represent the standard deviation.
P values <0.05 were assessed as statistically significant. (M-N) Co-labeling with Foxa2 revealed that Pax6 cells are extended more ventrally at E13.5
(white arrows). The dashed line marks the border in the Foxa2 expression domain. (O-T) Pax6 and green fluorescent protein (GFP) staining of
Ngn2−/− embryos shows no difference in the numbers of Pax6-expressing cells in the basal plate of the ventral midbrain at E11.5 (O-Q) and E13.5
(R-T). E, embryonic day; vMB: ventral midbrain.
Figure 8 Conditional inactivation of Uncx4.1 at E12.5 leads to
defects in the mDA neuron domain. (A-B) Tyrosine hydroxylase
(TH) staining on midbrain sections of Uncx4.1fl/+ and Cre-ER:
Uncx4.1del/- mice. (C-D) Immunohistochemistry (IHC) of dopamine
transporter (DAT) on ventral midbrain sections of Uncx4.1fl/+ and
Cre-ER:Uncx4.1del/- mice. Grey arrows show the substantia nigra (SN).
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Pax6-positive cells of the ventral midbrain are glutama-
tergic [28]. Using IHC Pax6 expression was not affected
at E11.5, and E12.5 in mutant embryos (Figure 7E-F, U).
However, starting with E13.5 the number of Pax6-
expressing cells was increased by 55% (Figure 7G-H, U)
and by around 26% at E17.5 (Figure 7I-J, U). Double
IHC against Pax6 and Foxa2 revealed, unlike at E12.5,
that the Pax6 expression domain was slightly extended
ventrally at E13.5 (Figure 7K-N). Further analysis using
ISH and IHC indicated that the expression of Uncx4.1 is
not affected in the midbrain of Pax6-deficient embryos
at E11.5 and E17.5 (data not shown). We then asked
whether the observed upregulation of Pax6 expression in
Uncx4.1-deficient midbrain is caused by the diminution
of Ngn2 transcription in Uncx4.1 mutant embryos. How-
ever, Pax6 expression was not modified in the basal plate
of Ngn2−/− embryos at all analyzed stages, indicating that
the increase of Pax6-positive cells in Uncx4.1−/− embryos
may not be directly related to the reduction of Ngn2
(Figure 7O-T). In none of the above realized experi-
ments we noted ectopic expression of glutamatergic
markers in the mDA domain, indicating that a fate
switch to a glutamatergic identity had not occurred. Our
findings demonstrate that Uncx4.1 may play a critical
role in the development of glutamatergic neuron sub-
groups in the ventral midbrain, and that the increased
numbers of Pax6-positive neurons are not directly
related to the partial depletion of Ngn2.
Conditional inactivation of Uncx4.1 leads to a partial loss
of mDA neurons in the SN of adult mutant mice
Since Uncx4.1-deficient mice die shortly after birth
[12,13], we created a conditional Uncx4.1 mutant in
order to examine mDA neurons in the adult midbrain.
This conditional Cre-ER:Uncx4.1 mutant was obtained
by crossing the floxed Uncx4.1 knockout line with an in-
ducible Cre-ER mouse line [34] and injected tamoxifen
at E12.5. Cre recombination efficiency was analyzed on
P0 brains using an Uncx4.1 antibody. Around 90% of
the Uncx4.1 signal was lost in Cre-ER:Uncx4.1del/- ani-
mals. Under such tamoxifen application conditions, and
as reported for the Cre-ER [34], we assume that atE14.5, 90% of Uncx4.1 gene activity is lost. To analyze
mDA neurons in adult Cre-ER:Uncx4.1del/- mice we per-
formed IHC against TH and DAT. Such mutants exhib-
ited a weak, but statistically not significant reduction in
TH-positive cells compared to control animals (n = 3).
However, the most lateral neurons of the SNpc always
appeared reduced in mutant as compared to control
midbrain (Figure 8, A-D, grey arrows and Additional file
3: Figure S3). Since almost all mDA precursors have
been generated before E12.5 when tamoxifen was
injected, but differentiation into mature neurons and mi-
gration still takes place, our findings suggest that
Uncx4.1 might be involved in maturation and/or cell mi-
gration, but not in the generation of mDA neurons.
Discussion
In recent years enormous efforts were made to identify
and characterize transcription factors controlling mDA
neurogenesis, including Msx1 [3], Foxa2 [4], Lmx1a [3],
Ngn2 [1,2], Nurr1 [6,35], En1/2 [36], Lmx1b [37] and
Pitx3 [19,21,38,39]. In the transition from VZ mDA
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these factors provide a complex regulatory network
required for full expansion of the heterogeneous
mDAergic field of the midbrain [40]. In this study we
provide evidence for an important novel role of the tran-
scription factor Uncx4.1 in mDA neuron development.
This role is exerted and confined in the critical phase of
transition from progenitors to mature mDA neurons,
roughly between E9.0 to E12.5, and it engages the pro-
neural gene Ngn2. During this temporal window
Uncx4.1 is required to sustain the expression of Ngn2.
This suggests that Uncx4.1 is mainly a differentiation
factor that may affect essential properties of mDA neu-
rons in this period. For instance, our analysis suggests a
possible implication of Uncx4.1 in the migration process
of mDA precursors. In this respect it is important to
note that Uncx4.1 deficiency causes a connectivity defect
in the pituitary complex [14]. In this study we found that
hypothalamic magnocellular neurons, neuroendocrine
cells in the hypothalamus, fail to fully innervate the pos-
terior pituitary, and instead run through the anterior pi-
tuitary. This points to an axon guidance defect in this
neuronal system.
The current study also demonstrates that midbrain ex-
pression of Uncx4.1 is not exclusive for mDA neurons. It
also includes GABAergic and glutamatergic neurons. We
show that the loss of Uncx4.1 provokes an increase in the
numbers of glutamatergic Pax6-marked cells in the ventral
midbrain, suggesting an additional important function for
Uncx4.1 activity in glutamatergic neurogenesis.
The expression of Uncx4.1 in mDA neurons
Developing midbrain dopaminergic neurons can be sub-
divided into three different groups. They arise from pro-
liferating committed neural stem cells, first as
postmitotic progenitors, then postmitotic precursors,
and finally mature mDA neurons. Mature mDA neurons
express the enzyme TH that is involved in the dopamine
biosynthesis. In this study we could show that Uncx4.1
is expressed in nearly all TH-positive cells at E11.5 indi-
cating that it is present in mature mDA neurons.
Uncx4.1 expression seems to be induced in mDA pro-
genitors that express Ngn2 [1,2]. This timing resembles
the expression of Nurr1, a central transcription factor in
the cell-specific expression and regulation of genes in
mDA neurons [41]. In the whole midbrain, Uncx4.1 is
absent from the VZ, but expressed in postmitotic neu-
rons. Using IHC and ISH, we further demonstrate that
Uncx4.1 is not restricted to a specific lineage but that it
is present in most neuronal subgroups during midbrain
development. This finding is consistent with a recent re-
port demonstrating Uncx4.1 expression in all neuronal
lineages of the olfactory bulb [15]. In conclusion, our
findings support the idea that this transcription factormight have a general and cell-type independent role dur-
ing neuronal development [15]. Furthermore, it may also
promote particular properties of specific neuronal type,
such as mDA neurons.
The potential role of Uncx4.1 in mDA neuron
development
Our analysis of Uncx4.1−/− embryos revealed a reduced
expression of several mDA neuron markers, and includ-
ing TH, DAT, Nurr1, and Pitx3. In addition, the num-
bers of Calbindin- and Calretinin-marked cells were
severely decreased in this context. Calbindin and Calreti-
nin are preferentially expressed in VTA neurons [23,24]
whereas Calbindin labels mDA neurons of the VTA
[2,42]. Therefore, the more pronounced reduction of
Calbindin- and Calretinin-marked neurons indicates,
that VTA neurons are possibly more affected by the ab-
sence of Uncx4.1 than those of the SN. This finding was
further corroborated by the reduced expression of Otx2,
a transcription factor expressed in mature mDA neurons
of the VTA but not of the SN at E17.5 embryos and
adult mice [25]. Although our findings indicate that the
mDA neurons of the VTA are more affected than those
of the SN, we could also observe reduced numbers of
mDA neurons in the SN. However, the minor decrease
of mDA neurons in Uncx4.1-deficient mice is consistent
with the notion that this factor only partially affects the
differentiation of mDA neurons. Moreover, it appears
that, although decreased, the level of Ngn2 expression is
still sufficient for the generation DA neurons. It is also
reasonable to assume that the loss of Uncx4.1 is com-
pensated by another factor. It was shown in C. elegans
that Unc-4, a homolog of Uncx4.1 [10,43], acts together
with a co-repressor and that these proteins are involved
in the correct specification of the transmitter phenotype
[22]. The persistent lower numbers of TH-positive neu-
rons in Uncx4.1 mutants at E11.5, as well as at E17.5 of
development, are consistent with the idea that the ab-
sence of Uncx4.1 does not provoke a delay in mDA
neuron generation. In contrast to what has been
described for the olfactory bulb of Uncx4.1−/− mice,
where cell death was reported [15], the lack of Uncx4.1
in the midbrain is not accompanied by an alteration in
proliferation or apoptosis. This may suggest that in
Uncx4.1-deficient mice the loss of a subpopulation of
dopaminergic neurons is compensated by the accumula-
tion of another neuronal cell type, which will be dis-
cussed below. Since Uncx4.1 is not expressed in the VZ
where cellular specification occurs, and in addition, the
majority of Uncx4.1-positive cells in the ventral mid-
brain are co-positive for TH at E11.5, it is more likely
that Uncx4.1 acts during differentiation and not during
specification of mDA neurons. The absence of Uncx4.1
from TH-positive cells at later stages (E17.5) supports
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critical window of differentiation of mDA neurons.
Accordingly, the numbers of mDA neurons is unaffected
at adult stages when Uncx4.1 was conditionally inacti-
vated at E12.5, although it seems that the neurons of the
SN are reduced. After their generation, mDA neurons
first migrate along the dorsal ventral axis before they mi-
grate laterally to their final destination. Since we could
not recognize a difference in the cell content of mDA
neurons in the conditional mutant mice, after deletion
of Uncx4.1 at E12.5, but a reduction in the SN, this may
suggest that Uncx4.1 is involved in the proper migration
of these neurons. This is consistent with an earlier find-
ing, where we could show that hypothalamic magno-
cellular neurons fail to fully innervate the posterior
pituitary, and instead they connect to the anterior pituit-
ary [14]. Moreover, it was shown that Unc-4 is involved
in the correct establishment of the innervation of VB
motor neurons in C.elegans [44-46]. This favors the hy-
pothesis that Uncx4.1 is possibly implicated in the cor-
rect axonal guidance of mDA neurons and that the
migration of mDA neurons to the SN is altered. The
proneural gene Ngn2 is required for neuronal differenti-
ation of mDA progenitors and starts to be expressed
around E10.75 [1,2]. Within the mDA neuron popula-
tion Ngn2 is exclusively present in dopaminergic neuron
progenitors and immature neurons. In the absence of
Uncx4.1, Ngn2 expression is down-regulated, providing
additional evidence that the observed alterations in
mDA neurons in Uncx4.1 mutant may be related to a
differentiation defect in the progenitor or immature
neuron pool. The transcription factor Nurr1 is expressed
in immature and mature neurons and found essential for
their maintenance [6,47,48]. It has been shown that
Nurr1-positive cells are nearly absent in Ngn2-deficient
embryos at E11.5 and that they recover around E13.5
[1]. In contrast to Ngn2 mutants, we did not observe
such a recovery of Nurr1-positive cells in Uncx4.1-defi-
cient mice. This is possibly due to the unaltered expres-
sion of Mash1 in the ventral midbrain [1]. Interestingly,
we could not detect Uncx4.1 expression in the ventral
midline of Ngn2-deficient midbrain. However, this may
simply be explained by the nonestablished postmitotic
neurons within the mDA domain of Ngn2 mutant at the
analyzed time points. The Co-IP experiment and the fact
that no binding sites for Uncx4.1 were identified on the
Ngn2 locus provide evidence that Uncx4.1 and Ngn2 do
not interact with each other. Therefore it is reasonable
to assume that another unknown factor may be involved
in the partial loss of mDA neurons provoked in Uncx4.1
mutant embryos, and that the downregulation of Ngn2
is indirectly related to the moderate decrease of this
neuron population. Overall, our results point to a mech-
anism of Uncx4-mediated differentiation events in thecritical E9.0 to 12.5 time window, and indirectly
engaging Ngn2.
The potential role of Uncx4.1 in midbrain glutamatergic
neuron development
As mentioned above the loss of a subpopulation of mDA
neurons may be compensated by the accumulation of an-
other neuronal cell type. In fact, we could not detect ec-
topic expression of glutamatergic neuron markers in the
mDA domain, which makes it unlikely that mDA neurons
change their cell fate. However, we found increased Brn3a-
mRNA signal in the ventral midbrain leading to the idea
that Uncx4.1 acts on glutamatergic neuron development.
The increase in the numbers of Pax6-positive neurons at
E13.5 in Uncx4.1-deficient mice favors this hypothesis. The
transcription factor Brn3a is expressed in glutamatergic
red nucleus neurons, which are located adjacent to the
mDA domain at E11.5 [17,28,31,32,49,50]. Since Nkx6.1 is
required for the proper development of Brn3a-positive red
nucleus neurons [18], the unaltered numbers of Nkx6.1-
positive cells indicate that the ventral glutamatergic pro-
genitors are normally established. During development, the
transcription factor Pax6 is expressed in a subset of gluta-
matergic neurons [28]. In this study, we demonstrate that
the number of Pax6-expressing cells is increased in
Uncx4.1−/− embryos starting with E13.5 and this alteration
persists until at least E17.5. The increase in Pax6-positive
cell number is not related to the downregulation of Ngn2
transcription. This is corroborated by the nonaltered ex-
pression of Pax6 in Ngn2−/− mutant mice. Taken together,
our findings suggest that Uncx4.1 acts on glutamatergic
neuron differentiation. In addition, the normal expression
of Uncx4.1 in Pax6-deficient midbrain at E11.5 may indi-
cate that Uncx4.1 acts upstream of Pax6. Interestingly
Ngn2-labeled glutamatergic neurons are more reduced in
the dorsal than in the ventral midbrain of Uncx4.1−/−
embryos. In this context, it was shown that Ngn2 promotes
the glutamatergic neurotransmitter fate by repressing the
GABAergic cell fate in the mouse cortex [51]. However, we
did not observe any difference in GABAergic marker ex-
pression in Uncx4.1-deficient mice, suggesting that the
remaining low level of Ngn2 is still sufficient to mediate
glutamatergic over GABAergic neuron development. This
finding is supported by the unaltered expression of the glu-
tamatergic neuron marker Brn3a in the dorsal midbrain.
Another explanation for the normal expression of
GABAergic markers might be that Ngn1 compensate for
the loss of Ngn2. Alternatively, Ngn2 itself may not be ne-
cessary for the development of a mesencephalic glutama-
tergic cell fate. Nakatani et al. (2007) showed in gain-of-
function studies, that Ngn1 promotes the glutamatergic
phenotype. Overall our results demonstrate that Uncx4.1 is
required for the proper development of midbrain glutama-
tergic neurons.
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In this study, we have shown that the transcription factor
Uncx4.1 is expressed in GABAergic, glutamatergic and
dopaminergic neurons of the developing midbrain. A
detailed analysis of the neuron population in the ventral
midbrain of Uncx4.1−/− embryos revealed a significant re-
duction in the content of mDA neurons. This study pro-
vides evidence that Uncx4.1 is a novel player in the
complex regulatory network of mDA neuron differenti-
ation and that it plays a role in the transition phase from
progenitors to mature mDA neurons. Furthermore, our
study uncovers that the loss of Uncx4.1 provokes an in-
crease in Pax6-positive neurons in the ventral midbrain,
suggesting another important function for Uncx4.1 in
midbrain glutamatergic neurogenesis.Methods
Animals
Animal experimentation and housing was performed in
agreement with the regulations of the animal welfare law
of Germany and approved by LAVES Institution of Low
Saxony (Approval Nr.:33.9-°©-‐4250204-°©-‐11/0402).
Generation and genotyping of Uncx4.1−/− [12],
Uncx4.1flox/flox [13], Cre-ER [34] Ngn2Kigfp [52] and Pax6
−/− [53] mice has been described previously. Ngn2Kigfp/Kigfp
are referred as Ngn2−/− in this article. Either wild-type ani-
mals or Uncx4.1-heterozygous animals were used as con-
trol for comparison with Uncx4.1−/− embryos. Such
controls are shown as Uncx4.1+/?. All mice were kept on
B6N background.
For conditional ablation of Uncx4.1 at E12.5 Uncx4.1
heterozygous mice were first crossed with Cre-ER mice
to obtain Cre-ER:Uncx4.1+/− mice. These mice were fur-
ther crossed to Uncx4.1fl/fl mice. 1 mg/10 g body weight
tamoxifen was injected to the pregnant female at E12.5.
The morning of the vaginal plug was considered as E0.5.Immunohistochemistry, in situ hybridization and X-gal
staining
Embryos were taken at the desired time point and used for
in situ hybridization (ISH) or immunohistochemistry
(ICH). Dissected brains or heads were placed in 4% PFA
for 1 to 16 hours according to their size. After fixation,
embryos were washed three times for ten minutes in
1 x PBS and, in case of cryoembedding followed by cryo-
protection, in 30% sucrose (in 1 x PBS), 30 minutes in 50%
tissue freezing medium (Jung; Leica, Nussloch, Germany)
in 30% sucrose and embedded in tissue-freezing medium.
In case of paraffin embedding, the tissue was dehydrated
after washing in 1 x PBS through ascending ethanol series
before it was transferred in isopropanol/toluene (through
an ascending isopropanol/toluene series) and finally em-
bedded in paraffin.ISH using digoxigenin-labeled single-stranded RNA
probes was performed on 18 μm thick cryosections accord-
ing to Moorman et al. [54]. For two-colored ISH Dig- and
Fluorescein-labeled probes were used. A detailed protocol
for two-colored ISH is available upon request. The follow-
ing in situ probes were used: Ngn2, Helt, Mash1, Uncx4.1,
Gad67, Lmx1a, Nkx2.2, Nkx6.1 and Brn3a.
For IHC, 10 μm thick cryo or paraffin sections were
used. Paraffin sections were hydrated through descending
ethanol series before boiling for one minute in unmasking
solution (1:100 in water, Vector Laboratories, Burlingame,
CA, USA). Afterwards, the sections were placed three
times for five minutes in 1 x PBS prior to blocking (in 10%
FCS + 0.01% Triton or 1% BSA + 0.01% Triton in PBS,
sterile filtered). Primary antibodies were incubated over-
night or for 72 hours at 4 °C in blocking solution. Second-
ary antibodies were diluted 1:750 in blocking solution and
incubated for 70 minutes at room temperature. After sec-
ondary antibody sections were rinsed three times in
1 x PBS before mounting in Vectrashield with DAPI (Vector
Laboratories). Cryosections were processed the same way
without descending ethanol series and boiling.
Primary antibodies used were rabbit anti-Uncx4.1
(1:750), goat anti-Hnf3ß (1:150, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-TH (1:300, Chemicon,
Billerica, MA, USA), mouse anti-TH (1:5000, Sigma-
Aldrich, St. Louis, MO, USA), rat anti-DAT (1:100, Santa
Cruz Biotechnology), rabbit anti-Pitx3 (1:1000), goat anti-
Nurr1 (1:100, R&D Systems, Minneapolis, MN, USA),
rabbit anti-Pax6 (1:300, Covance, Princeton, NJ, USA),
mouse anti-Pax6 (1:100, DSHB, Iowa City, IA, USA),
rabbit anti-Nkx6.1 (1:3000 [55]), mouse anti-Nkx6.1
(1:100, DSHB), rabbit anti-Calbindin (1:200, Swant, Bellin-
zona, Switzerland), rabbit anti-Calretinin (1:300, Sigma-
Aldrich), chicken anti-GFP (1:500, Abcam, Cambridge,
MA, USA), anti-BrdU (1:50, Sigma-Aldrich), mouse anti-
Ngn2 (1:100, R&D Systems) and rabbit anti-Olig2 (1:500,
Chemicon). Secondary antibodies were either Alexa488-
or Alexa594-conjugated and raised against mouse, rabbit,
rat, chicken or goat (Invitrogen, Carlsbad, CA, USA).
X-gal staining was performed as describes previously [56].
Pictures were taken with an Olympus BX60 fluores-
cent microscope or with an Olympus SZX 12 fluorescent
microscope (Olympus, Tokyo, Japan). Confocal pictures
were taken with Leica TCS SP5 confocal microscope
(Leica Microsystems, Germany). Pictures were processed
with Adobe Photoshop (Version 10.0) by overlaying the
pictures, adjusting brightness, contrast and size.BrdU labeling and TUNEL assay
100 μl/10 g bodyweight BrdU (15 mg/ml in PBS) was
intraperitoneally injected into pregnant females at E10.5
or E14.5. In the case of the E10.5-day-old embryos, the
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the case of the E14.5-day-old embryos, the animal was
sacrificed 45 minutes after the injection. Embryos were
processed for embedding in cryo media, followed by
IHC against anti-BrdU (1:100, Roche, Basil, Switzerland)
or against mouse anti-BrdU (1:100, Roche) together with
rabbit anti-TH (1:200, Chemicon). Apoptosis was
detected using the TUNEL assay. The TUNEL Apoptosis
detection kit (Millipore, Billerica, MA, USA) was used
following the manufacturer’s instructions.Cell counting and statistical analysis
Cell counts were done on images of coronal sections or
directly under the microscope along the rostral-caudal axis
of the midbrain. For embryonic stages, every fourth and
for adult stages every eighth section was counted and the
average was calculated for at least three animals. The two-
tailed unpaired Student’s t test was applied on the
averages. Statistical significance was considered if P ≤0.05.Cell culture, Co-immunoprecipitation (Co-IP) and western
blotting (WB)
Hela cells were cultured in DMEM medium with 10%
fetal calf serum (FCS). For Co-IP the cells were seeded
into a 10 cm dish. When 80 to 90% confluent cells were
transfected using Lipofectamine 2000 (Invitrogen) fol-
lowing the manufacturer’s manual. During this process
either DMEM or Opti-MEM serum-free medium was
used. The next morning, the proteasome inhibitor
MG132 (Sigma-Aldrich) was applied to the cells at a
final concentration of 20 μm. Twenty-four hours after
transfection the cells were harvested and Co-IP using
FLAG tagged beads was performed according to the
manufacturer’s recommendation (Sigma-Aldrich). For
Co-IP Uncx4.1-c-myc was co-transfected with Ngn2-
FLAG. Detailed information about the plasmids is avail-
able upon request. After performing the Co-IP the
samples were applied on a 12% SDS gel. Afterwards, the
proteins were transferred to a membrane overnight fol-
lowed by 90 minutes blocking in 5% milk powder in
PBT. After blocking, the first antibody was incubated
overnight at 4 °C. The next day, the membrane was
washed three times in 1 x PBT and the second antibody
was applied for one hour at room temperature. After
three times washing for 30 minutes in 1 x PBT the protein
was detected using Super Signal West Pico and Super
Signal West Femto kit (both Pierce, Rockford, IL, USA).
First antibodies used are rabbit anti-FLAG (1:1000
Sigma-Aldrich) and mouse anti-c-myc (1:500 Santa Cruz
Technology). Secondary antibodies used are anti-rabbit-
HRP (1:10000 Dianova, Hamburg, Germany) and anti-
mouse-HRP (10000 Dianova).Additional files
Additional file 1: Figure S1. Uncx4.1-deficient midbrain shows no
difference in cell proliferation at E11.5 as compared to control.
(A-B) Immunohistochemistry (IHC) against 5-bromo-2'-deoxyuridine
(BrdU) on coronal sections of E11.5 embryos after 24 hours of BrdU
injection. (C-D) IHC against BrdU and tyrosine hydroxylase (TH) 24 hours
after BrdU injection. BrdU was injected at E10.5 and the animals were
sacrificed 24 hours later at E11.5. E, embryonic day.
Additional file 2: Figure S2. Co-immunoprecipitation (Co-IP) of
Uncx4.1 and Ngn2 provide no evidence for an interaction between the
two factors. Hela cells were co-transfected as indicated and the lysates
were used for a Co-IP assay using Flag tagged beads. Western blot (WB)
analysis was performed using anti-c-myc and anti-Flag antibody.
Additional file 3: Figure S3. Conditional inactivation of Uncx4.1 at
E12.5 results in defects in the substantia nigra (SN) as documented by
alterations in dopamine transporter (DAT) expression (A-H), and tyrosine
hydroxylase (TH) expression (I-P) in adult animals. The white arrows point
to the region of the SN, which is affected in the mutant animals.
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